Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) kicked off on Monday, down -10.62% from the previous trading day, before settling in for the closing price of $1.70. Over the past 52 weeks, LXRX has traded in a range of $0.92-$3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 186.21%. While this was happening, its average annual earnings per share was recorded 11.75%. With a float of $351.32 million, this company’s outstanding shares have now reached $361.49 million.
Let’s determine the extent of company efficiency that accounts for 285 employees.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lexicon Pharmaceuticals Inc is 2.81%, while institutional ownership is 73.53%. The most recent insider transaction that took place on Nov 16 ’23, was worth 94,797. In this transaction Chief Executive Officer of this company bought 90,000 shares at a rate of $1.05, taking the stock ownership to the 914,359 shares. Before that another transaction happened on Nov 10 ’23, when Company’s Chief Executive Officer bought 10,000 for $1.01, making the entire transaction worth $10,100. This insider now owns 824,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 11.75% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Take a look at Lexicon Pharmaceuticals Inc’s (LXRX) current performance indicators. Last quarter, stock had a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 150.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Looking closely at Lexicon Pharmaceuticals Inc (NASDAQ: LXRX), its last 5-days average volume was 4.01 million, which is a jump from its year-to-date volume of 3.68 million. As of the previous 9 days, the stock’s Stochastic %D was 7.46%. Additionally, its Average True Range was 0.18.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 3.03%, which indicates a significant increase from 1.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.84% in the past 14 days, which was higher than the 80.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8609, while its 200-day Moving Average is $1.7737. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $1.5883. Second resistance stands at $1.6617. The third major resistance level sits at $1.7033. If the price goes on to break the first support level at $1.4733, it is likely to go to the next support level at $1.4317. Should the price break the second support level, the third support level stands at $1.3583.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
The company with the Market Capitalisation of 547.66 million has total of 246,237K Shares Outstanding. Its annual sales at the moment are 1,200 K in contrast with the sum of -177,120 K annual income. Company’s last quarter sales were recorded 1,130 K and last quarter income was -48,400 K.
